USD10
CLLS Shares
About CellectisCellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
USD10
CLLS Shares
About CellectisCellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Stats
TRADING WINDOW
Closed
OPENS AT
Jun 8 at 1:30 PM GMT+0
MARKET CAP
$307.87M
OPEN PRICE
Not enough data
LOW (1Y)
$1.33
HIGH (1Y)
$5.48
LOW (24H)
Not enough data
HIGH (24H)
Not enough data
VOLUME (24H)
Not enough data
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $3.06 | 0.00% |
1 Week | $3.52 | |
1 Month | $4.10 | |
1 Year | $1.43 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
